A Study of RPL554 in Patients With Cystic Fibrosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-08

Study Completion Date

2017-11-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

NCT03093714

Cystic Fibrosis

COMPLETED PHASE1

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

NCT03540524

Cystic Fibrosis

COMPLETED PHASE1

A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis

NCT01543191

Cystic Fibrosis

COMPLETED PHASE1

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

NCT03119649

Cystic Fibrosis

COMPLETED PHASE2

Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes

NCT00231192

Diabetes

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Higher Dose RPL554

Single dose of inhaled 6 mg RPL554

Group Type EXPERIMENTAL

RPL554

Intervention Type DRUG

RPL554 suspension administered using a nebuliser

Lower dose RPL554

Single dose of inhaled 1.5 mg RPL554

Group Type EXPERIMENTAL

RPL554

Intervention Type DRUG

RPL554 suspension administered using a nebuliser

Placebo

Inhaled placebo dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo solution administered using a nebuliser

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RPL554

RPL554 suspension administered using a nebuliser

Intervention Type DRUG

Placebo

Placebo solution administered using a nebuliser

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.

2\. Male or female aged ≥18 years at the time of informed consent. Females of childbearing potential must have been using a consistent and reliable form of contraception (see Appendix 1) from the last menses before the first study treatment administration, and must commit to continue to do so during the study and for 3 months after the last dose of study treatment.

3\. Have a 12-lead ECG recording at screening (Visit 1) and Visit 2 pre-dose showing the following:
* Heart rate between 45 and 90 beats per minute
* QT interval corrected for heart rate using Fridericia's formula (QTcF) interval ≤450 msec
* QRS interval ≤120 msec
* PR interval ≤220 msec
* No clinically significant abnormality including morphology (e.g. left bundle branch block, atrioventricular nodal dysfunction, ST segment abnormalities) 4. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.

5\. Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) with a minimum weight of 40 kg.

6\. Patients with a genetic diagnosis of CF. 7. Spirometry at screening demonstrating an FEV1 ≥40% and ≤80% of predicted normal.

8\. Capable of withdrawing from long acting bronchodilators1 until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study treatment.

9\. Clinically stable CF in the 2 weeks prior to randomisation (Visit 2).

Exclusion Criteria

1. History of cirrhotic liver disease or portal hypertension.
2. CF exacerbation requiring hospitalisation in the month prior to screening (Visit 1) or prior to randomisation (Visit 2).
3. Use of oral or intravenous antibiotics (in additional to usual maintenance therapy) in the 2 weeks prior to screening (Visit 1) or randomisation (Visit 2).
4. Other non-CF related respiratory disorders: Patients with a current diagnosis of active tuberculosis, lung cancer, sarcoidosis, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
5. Previous lung resection or lung transplant.
6. History of, or reason to believe a patient has, drug or alcohol abuse within the past 3 years.
7. Received an experimental drug within 3 months or five half-lives, whichever is longer.
8. Patients with a history of chronic uncontrolled disease including, but not limited to, cardiovascular (including arrhythmias), endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological or ophthalmic diseases that the Investigator believes are clinically significant.
9. Documented cardiovascular disease: angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.
10. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening (Visit 1) or will not have fully recovered from surgery, or planned surgery through the end of the study.
11. Infection with nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus (MRSA), or Burkholderia species.
12. Use of immune-suppression; long term use of prednisolone ≥10 mg/day.
13. History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell).
14. Clinically significant abnormal values for safety laboratory tests (haematology, biochemistry or urinalysis) at screening (Visit 1), as determined by the Investigator.
15. A disclosed history or one known to the Investigator, of significant non-compliance in previous investigational studies or with prescribed medications.
16. Requires oxygen therapy, even on an occasional basis.
17. Pregnancy or lactation (female subjects only).
18. Any other reason that the Investigator considers makes the patient unsuitable to participate. -

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No